These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 20656417)
21. Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models. Meier D; Botter SM; Campanile C; Robl B; Gräfe S; Pellegrini G; Born W; Fuchs B Int J Cancer; 2017 Apr; 140(7):1680-1692. PubMed ID: 27943293 [TBL] [Abstract][Full Text] [Related]
22. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Cramers P; Ruevekamp M; Oppelaar H; Dalesio O; Baas P; Stewart FA Br J Cancer; 2003 Jan; 88(2):283-90. PubMed ID: 12610515 [TBL] [Abstract][Full Text] [Related]
23. Tissue levels, histologic changes and plasma pharmacokinetics of meta-Tetra (hydroxyphenyl) chlorin (mTHPC) in the cat. Campbell GA; Bartels KE; Arnold C; Healey T; Cowell RL; Lucroy MD; Ronn AM Lasers Med Sci; 2002; 17(2):79-85. PubMed ID: 12111590 [TBL] [Abstract][Full Text] [Related]
25. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes. Maugain E; Sasnouski S; Zorin V; Merlin JL; Guillemin F; Bezdetnaya L Oncol Rep; 2004 Sep; 12(3):639-45. PubMed ID: 15289849 [TBL] [Abstract][Full Text] [Related]
26. Photosensitizing effects of m-tetrahydroxyphenylchlorin on human tumor xenografts: correlation with sensitizer uptake, tumor doubling time and tumor histology. Ris HB; Li Q; Krueger T; Lim CK; Reynolds B; Althaus U; Altermatt HJ Int J Cancer; 1998 Jun; 76(6):872-4. PubMed ID: 9626355 [TBL] [Abstract][Full Text] [Related]
27. Localization of liposomal mTHPC formulations within normal epithelium, dysplastic tissue, and carcinoma of oral epithelium in the 4NQO-carcinogenesis rat model. de Visscher SA; Witjes MJ; van der Vegt B; de Bruijn HS; van der Ploeg-van den Heuvel A; Amelink A; Sterenborg HJ; Roodenburg JL; Robinson DJ Lasers Surg Med; 2013 Dec; 45(10):668-78. PubMed ID: 24174342 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of tetra(m-hydroxyphenyl)chlorin in human plasma and individualized light dosimetry in photodynamic therapy. Glanzmann T; Hadjur C; Zellweger M; Grosiean P; Forrer M; Ballini JP; Monnier P; van den Bergh H; Lim CK; Wagnières G Photochem Photobiol; 1998 May; 67(5):596-602. PubMed ID: 9613244 [TBL] [Abstract][Full Text] [Related]
29. Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo. Reshetov V; Lassalle HP; François A; Dumas D; Hupont S; Gräfe S; Filipe V; Jiskoot W; Guillemin F; Zorin V; Bezdetnaya L Int J Nanomedicine; 2013; 8():3817-31. PubMed ID: 24143087 [TBL] [Abstract][Full Text] [Related]
30. Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols. Schouwink H; Ruevekamp M; Oppelaar H; van Veen R; Baas P; Stewart FA Photochem Photobiol; 2001 Apr; 73(4):410-7. PubMed ID: 11332037 [TBL] [Abstract][Full Text] [Related]
31. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. Andrejevic-Blant S; Hadjur C; Ballini JP; Wagnières G; Fontolliet C; van den Bergh H; Monnier P Br J Cancer; 1997; 76(8):1021-8. PubMed ID: 9376261 [TBL] [Abstract][Full Text] [Related]
32. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. van Geel IP; Oppelaar H; Marijnissen JP; Stewart FA Radiat Res; 1996 May; 145(5):602-9. PubMed ID: 8619026 [TBL] [Abstract][Full Text] [Related]
33. mTHPC-mediated photodynamic therapy is effective in the metastatic human 143B osteosarcoma cells. Reidy K; Campanile C; Muff R; Born W; Fuchs B Photochem Photobiol; 2012; 88(3):721-7. PubMed ID: 22268498 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Ma L; Moan J; Berg K Int J Cancer; 1994 Jun; 57(6):883-8. PubMed ID: 8206681 [TBL] [Abstract][Full Text] [Related]
35. Uptake and localisation of mTHPC (Foscan) and its 14C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: a comparative study. Blant SA; Glanzmann TM; Ballini JP; Wagnières G; van den Bergh H; Monnier P Br J Cancer; 2002 Dec; 87(12):1470-8. PubMed ID: 12454779 [TBL] [Abstract][Full Text] [Related]
36. Photodynamic effects of mTHPC on human colon adenocarcinoma cells: photocytotoxicity, subcellular localization and apoptosis. Leung WN; Sun X; Mak NK; Yow CM Photochem Photobiol; 2002 Apr; 75(4):406-11. PubMed ID: 12003131 [TBL] [Abstract][Full Text] [Related]
37. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. Teiten MH; Bezdetnaya L; Merlin JL; Bour-Dill C; Pauly ME; Dicato M; Guillemin F J Photochem Photobiol B; 2001 Sep; 62(3):146-52. PubMed ID: 11566278 [TBL] [Abstract][Full Text] [Related]
38. Enhancement of meta-tetrahydroxyphenylchlorin-sensitized photodynamic treatment on human tumor xenografts using a water-soluble vitamin E analogue, Trolox. Melnikova VO; Bezdetnaya LN; Brault D; Potapenko AY; Guillemin F Int J Cancer; 2000 Dec; 88(5):798-803. PubMed ID: 11072251 [TBL] [Abstract][Full Text] [Related]
39. mTHPC mediated, systemic photodynamic therapy (PDT) for nonmelanoma skin cancers: Case and literature review. Horlings RK; Terra JB; Witjes MJ Lasers Surg Med; 2015 Dec; 47(10):779-87. PubMed ID: 26462858 [TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC). Mikvy P; Messman H; MacRobert AJ; Pauer M; Sams VR; Davies CL; Stewart JC; Bown SG Br J Cancer; 1997; 76(6):713-8. PubMed ID: 9310235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]